Bipolar Disorder — Myths vs Reality FAQs

Talk to Dr. Samuel directly — your first 20 minutes are free.

Most people who reach out here don’t feel ready to talk on the phone. Start whichever way feels safest.

Text me what’s going on

The message is already written — just press send. I reply personally: usually within a few hours, always within 24.

Or have me call you — you pick the time →

No forms, no gatekeepers, no obligation. English or فارسی.

Call for a Free 20-Minute Consult — 6047210604
Evidence-based answers separating myths from facts about bipolar I, II, cyclothymia, mania, hypomania, treatment, and living well — backed by peer-reviewed research from APA, NIMH, ISBD, Lancet, JAMA, and leading psychiatric journals.
About this guide: 50 of the most-searched questions about bipolar disorder, organized into 5 sections that systematically address common myths and stigma with current scientific evidence. All claims are linked to numbered citations [1]–[150].
Crisis resources: If you or someone with bipolar disorder is in danger, call 911. People with bipolar disorder have ~10-15x higher suicide risk than the general population [1] — but treatment dramatically reduces this risk [2].

Section 1: What Is Bipolar Disorder? Definitions & Diagnosis (Q1–Q10)

Q1. What is bipolar disorder?

Bipolar disorder (BD) is a chronic mental health condition characterized by recurring episodes of mania, hypomania, depression, and periods of euthymia (mood stability) [3]. Per DSM-5-TR, it’s classified into bipolar I (manic episodes), bipolar II (hypomanic + depressive episodes, no full mania), cyclothymia (sub-threshold cycling), and bipolar/related disorders due to other causes [3]. The ICD-11 classification is similar [4].

Q2. How common is bipolar disorder?

Across World Mental Health surveys of 61,392 adults in 11 countries, the aggregate lifetime prevalence of bipolar spectrum disorder was 2.4%, with prevalence varying across sites [151]. In the US National Comorbidity Survey Replication, lifetime prevalence was 1.0% for bipolar I, 1.1% for bipolar II, and 2.4% for subthreshold bipolar disorder [106]. WHO ranks bipolar disorder among the top 10 leading causes of disability worldwide [6].

Q3. What is the difference between bipolar I and bipolar II?

Bipolar I requires at least one manic episode (severe, lasting ≥7 days, often with psychosis or hospitalization). Bipolar II requires at least one hypomanic episode (less severe, ≥4 days) AND one major depressive episode, but NO full mania [3]. Bipolar II is not “milder” — depressive episodes are typically longer and more frequent, and suicide risk may actually be higher [7].

Q4. What is mania?

A manic episode is at least 1 week of abnormally elevated, expansive, or irritable mood plus increased energy/activity, accompanied by ≥3 symptoms (≥4 if mood is only irritable): inflated self-esteem/grandiosity, decreased need for sleep, more talkative, racing thoughts, distractibility, increased goal-directed activity or psychomotor agitation, excessive risky behavior [3]. Severe enough to impair functioning or require hospitalization, or with psychotic features [3].

Q5. What is hypomania?

Hypomania has the same symptoms as mania but lasts ≥4 days, is less severe (no marked impairment, no psychosis, no hospitalization), and is observable by others as a clear change from baseline [3]. Hypomania can feel productive or pleasant (“the up”) but typically leads to depression and is a defining feature of bipolar II disorder [3][7].

Q6. What is bipolar depression and how is it different from major depression?

Bipolar depression has the same core DSM-5-TR symptoms as unipolar depression but with key differences: more atypical features (hypersomnia, hyperphagia, leaden paralysis), more psychomotor retardation, more psychotic features, and earlier age of onset [8]. Importantly, antidepressants alone can trigger mania or rapid cycling in bipolar disorder, so accurate diagnosis is critical [8][9].

Q7. What is cyclothymia?

Cyclothymic disorder is at least 2 years (1 year in children/adolescents) of numerous hypomanic and depressive symptoms that don’t meet full criteria for hypomania or major depression, with symptoms present at least half the time [3].

Q8. How is bipolar disorder diagnosed?

Diagnosis is clinical, based on careful history (often requiring informants who’ve witnessed manic/hypomanic episodes), DSM-5-TR or ICD-11 criteria, mental status exam, and ruling out medical, substance-induced, or other psychiatric causes [3][11]. Validated screening tools include the Mood Disorder Questionnaire (MDQ) and Hypomania Checklist (HCL-32) [12][13]. There are no blood tests or brain scans that diagnose bipolar [11].

Q9. Why is bipolar disorder often misdiagnosed?

Studies show average diagnostic delay is 6–10 years from symptom onset [14]. Reasons include: people seek help during depression (not mania, which can feel good), hypomania can be missed, comorbid conditions (anxiety, ADHD, substance use) mask symptoms, and stigma reduces help-seeking [14][15]. In a US survey of 600 people with bipolar disorder, 69% had been misdiagnosed, most often with unipolar depression [152].

Q10. At what age does bipolar disorder typically begin?

Average age of onset is 20–25 years, with most cases starting between adolescence and early adulthood [16]. Earlier onset is associated with worse course, more episodes, and higher comorbidity [16].

Section 2: Common Myths Debunked (Q11–Q20)

Q11. MYTH: “Bipolar means just having mood swings.”
REALITY:

Normal mood swings (frustration, joy, sadness in response to events) are very different from bipolar episodes [3][17]. Bipolar episodes last days to weeks, involve significant change in energy/activity/sleep/cognition (not just emotion), occur without clear external triggers, and impair functioning. Calling everyday mood changes “bipolar” minimizes a serious illness and contributes to stigma [17].

Q12. MYTH: “People with bipolar are dangerous or violent.”
REALITY:

This is largely false and harmful. Studies show people with bipolar disorder, when treated, are no more violent than the general population [18]. The vast majority of violence-by-mentally-ill is committed by individuals with untreated severe symptoms combined with substance abuse [18][19]. People with bipolar disorder are FAR more likely to be victims of violence than perpetrators [19].

Q13. MYTH: “Bipolar is just a mood that you can snap out of.”
REALITY:

Bipolar disorder is a brain-based illness with strong genetic, neurobiological, and structural underpinnings — it cannot be willpower-resolved [20][21]. A twin study estimated the heritability of bipolar disorder at about 85% [153]. Brain imaging shows differences in prefrontal cortex, amygdala, and white matter connectivity [21]. It requires ongoing treatment, not willpower [22].

Q14. MYTH: “Mania is fun/productive — people with bipolar enjoy it.”
REALITY:

Mild hypomania can feel pleasant, but full mania is dangerous and distressing — it often involves psychotic symptoms, severely impaired judgment, financial ruin, broken relationships, legal trouble, and hospitalization [22]. Most people with bipolar describe mania in retrospect as terrifying or destructive, not enjoyable [22].

Q15. MYTH: “Bipolar = creative genius.”
REALITY:

While there’s a modestly elevated rate of bipolar in creative professionals (especially writers, artists, musicians), the majority of people with bipolar are NOT exceptionally creative, and most highly creative people do NOT have bipolar disorder [24]. Romanticizing bipolar as “creative genius” minimizes suffering and may discourage treatment, fearing loss of creativity. With proper treatment, creativity is preserved or enhanced [24][25].

Q16. MYTH: “Medication for bipolar zombifies you.”
REALITY:

Modern bipolar medications, when properly dosed and monitored, allow most people to function fully and feel like themselves [26]. Some medications cause sedation or cognitive blunting, especially at high doses, but adjustments are typically possible [26]. Untreated bipolar disorder causes far more cognitive impairment than properly managed medication [26][27]. Many people on lithium or other mood stabilizers describe feeling “more themselves” with stable mood [26].

Q17. MYTH: “Bipolar disorder is rare.”
REALITY:

An estimated 4.4% of US adults experience bipolar disorder at some point in their lives, and 2.8% in a given year (NIMH) [161]. In the US alone, that means 5–10 million adults [28]. An estimated 4.4% of US adults experience bipolar disorder at some point in their lives, and 2.8% in a given year (NIMH) [154].

Q18. A twin study estimated the heritability of bipolar disorder at about 85% [153].
REALITY:

Bipolar is primarily a biological disorder with strong genetic basis (60–85% heritability) [20]. Childhood trauma can increase risk and worsen course in genetically predisposed individuals, but it does not “cause” bipolar in the absence of biological vulnerability [29]. Blaming parents or trauma alone misunderstands the science and adds harmful stigma [20][29].

Q19. MYTH: “Once stable, you can stop bipolar medication.”
REALITY:

This is one of the most dangerous misconceptions. Stopping mood stabilizers (especially lithium) abruptly causes relapse within months in most cases and can trigger refractory episodes harder to treat than original ones [30]. APA, NICE, and CANMAT guidelines recommend long-term, often lifelong, maintenance medication for most people with bipolar I disorder [30][31]. Any medication changes should be made gradually and with psychiatric supervision [30].

Q20. MYTH: “Bipolar disorder is the same as borderline personality disorder.”
REALITY:

Bipolar involves discrete mood episodes lasting days-weeks; BPD involves rapid emotional reactivity to interpersonal triggers, often within hours.

Section 3: Causes, Course & Comorbidities (Q21–Q30)

Q21. What causes bipolar disorder?

A 2019 genome-wide association study identified 30 genetic loci associated with bipolar disorder [34]. No single cause; no one to blame [20].

Q22. Is bipolar genetic?

Yes — strongly. However, having a relative with bipolar doesn’t guarantee developing it. Multiple genes contribute small amounts of risk; major loci include CACNA1C, ANK3, ODZ4 [34]. Genetic testing for clinical diagnosis is not yet routine [34].

Q23. What triggers bipolar episodes?

Common triggers per longitudinal studies: sleep disruption (one of the strongest), substance use (especially alcohol, cannabis, stimulants), stress, seasonal changes (spring/summer mania, fall/winter depression in many), life events (positive or negative), antidepressants without mood stabilizers, and hormonal changes (postpartum, perimenopause) [36][37]. Identifying personal triggers is a core treatment strategy [36].

Q24. What is rapid cycling?

Rapid cycling is defined as 4+ mood episodes in 12 months [3]. Rapid cycling affects between 5% and 33% of people with bipolar disorder in a given year and 26%–43% over a lifetime; its only confirmed close association is with female gender, and its link to bipolar II is disputed [155]. Antidepressants can induce rapid cycling. It tends to be harder to treat and may require specific approaches like lamotrigine, valproate, or thyroid augmentation [38][39].

Q25. What are mixed features?

Mixed features (per DSM-5-TR) are when manic and depressive symptoms occur simultaneously — for example, depression with racing thoughts, agitation, and insomnia, or mania with tearfulness and suicidal thinking [3]. Mixed states are particularly dangerous, with the highest suicide risk of any bipolar phase [40]. Treatment differs from “pure” mania or depression [40].

Q26. What’s the typical course of bipolar disorder?

Highly variable. With proper treatment, many people have long periods of stability (months to years) between episodes [41]. Without treatment, episodes typically become more frequent and severe over time (“kindling effect”) [42]. Even with treatment, residual symptoms (mainly subthreshold depression) are common [41]. Long-term outcomes have improved significantly since the introduction of lithium and other mood stabilizers [42].

Q27. What conditions commonly co-occur with bipolar disorder?

Most people with bipolar spectrum disorder have at least one other lifetime mental disorder, particularly anxiety disorders [106]. Cardiovascular disease, diabetes, obesity, and thyroid disease are also more common, partly due to medication effects and partly to lifestyle factors [43][44]. Comprehensive treatment addresses comorbidities [43].

Q28. How dangerous is bipolar disorder?

Suicide rates in bipolar disorder vary between studies but are approximately 20–30 times greater than in the general population [156]. Treatment dramatically reduces this risk — lithium specifically has antisuicidal effects beyond mood stabilization [2][45]. Bipolar also reduces life expectancy by 8–14 years, mainly from cardiovascular disease and suicide [44].

Q29. Can bipolar develop later in life?

Late-onset cases require careful medical workup. True idiopathic bipolar with first onset after 60 is rare [16].

Q30. Is there cognitive decline in bipolar disorder?

The deficit is mild on average and improves with treatment, but recurrent episodes appear to worsen it (“neuroprogression”).

Section 4: Treatment & Medications (Q31–Q40)

Q31. Is bipolar disorder treatable?

Yes — highly treatable, though not curable [31]. Most people achieve significant mood stability with proper treatment combining medication, psychotherapy, lifestyle management, and social support. Early intervention and consistent treatment improve long-term outcomes substantially [49].

Q32. What is lithium and why is it considered a gold-standard treatment?

Lithium is a mood stabilizer used since the 1940s and remains a first-line treatment per ISBD, CANMAT, NICE, and APA guidelines [31][50]. A meta-analysis of randomised trials found lithium was more effective than placebo in reducing suicides in people with mood disorders [157]. It has neuroprotective effects but requires monitoring (kidney, thyroid, blood levels) due to narrow therapeutic window [50][51].

Q33. What other medications treat bipolar?

Major categories: (1) other mood stabilizers — valproate, lamotrigine, carbamazepine; (2) atypical antipsychotics — quetiapine, olanzapine, aripiprazole, lurasidone, risperidone, cariprazine; (3) antidepressants (with caution, only with mood stabilizers); (4) thyroid hormone augmentation; (5) ECT for severe/treatment-resistant cases [31][52]. Choice depends on episode type, prior response, side effects, and comorbidities [31][52].

Q34. Can antidepressants be used in bipolar disorder?

This is controversial. Antidepressants alone can trigger mania or rapid cycling in bipolar [53]. ISBD task force guidelines recommend: (1) avoid antidepressants in bipolar I if possible, (2) only use combined with mood stabilizers, (3) avoid in mixed states or rapid cycling, and (4) discontinue after acute depression resolves rather than continuing as maintenance [53]. Quetiapine, lurasidone, and lamotrigine are preferred for bipolar depression [53][54].

Q35. What psychotherapies work for bipolar disorder?

Evidence-based psychotherapies include: psychoeducation, family-focused therapy (FFT), cognitive-behavioral therapy (CBT), interpersonal and social rhythm therapy (IPSRT), and dialectical behavior therapy (DBT) [55]. In a network meta-analysis of 39 randomised trials, structured psychotherapies added to medication were associated with lower recurrence rates than control treatments [158]. Therapy alone is NOT sufficient for most people with bipolar I, but is essential alongside medication [55].

Q36. What is interpersonal and social rhythm therapy (IPSRT)?

IPSRT, developed by Frank et al. specifically for bipolar disorder, focuses on stabilizing daily routines and sleep-wake cycles (a known trigger for episodes) plus addressing interpersonal issues [57]. In a network meta-analysis of 39 randomised trials, structured psychotherapies added to medication were associated with lower recurrence rates than control treatments [158]. Maintaining regular sleep, meals, and activity timing is one of the most evidence-based bipolar self-management strategies [57].

Q37. Is electroconvulsive therapy (ECT) used for bipolar?

In a study of 522 patients with bipolar disorder, ECT response rates were 68% for bipolar depression, 73% for mixed states, and 75% for mania [159]. It’s particularly valuable in pregnancy, severe suicidality, mixed states, and catatonia. Modern ECT minimizes cognitive side effects through ultrabrief pulses and unilateral placement. Maintenance ECT can prevent relapse in select cases [59][60].

Q38. What about transcranial magnetic stimulation (TMS) and ketamine?

Repetitive TMS is FDA-approved for unipolar depression and shows growing evidence for bipolar depression as adjunctive treatment [61]. Ketamine and esketamine show rapid antidepressant effects in bipolar depression but require caution given limited data on mania induction; current guidelines suggest careful use in treatment-resistant cases [61][62].

Q39. What are the side effects of bipolar medications?

Vary by medication: lithium (tremor, thirst, weight gain, kidney/thyroid effects), valproate (weight gain, hair loss, teratogenic), lamotrigine (rash including rare Stevens-Johnson), atypical antipsychotics (weight gain, metabolic syndrome, sedation, EPS) [52][63]. Most are manageable with monitoring and dose adjustment. Untreated bipolar carries far worse risks than properly managed medication [52][63].

Q40. How long do you need to take medication?

Bipolar II may sometimes be managed with shorter courses, but most people benefit from long-term treatment. The decision is individualized based on episode history, severity, and response [31][64].

Section 5: Living Well, Relationships & Recovery (Q41–Q50)

Q41. Can you live a full life with bipolar disorder?

Yes — many people with bipolar disorder live fulfilling lives with successful careers, relationships, and families [49]. Outcomes are best with: early diagnosis, consistent medication, evidence-based therapy, supportive relationships, healthy lifestyle, and active engagement in treatment [49]. Public figures who openly live with bipolar — including writers, athletes, actors, and CEOs — illustrate that diagnosis is not destiny.

Q42. What lifestyle changes help bipolar disorder?

Strong evidence supports: regular sleep schedule (most important), regular exercise, Mediterranean-style diet, abstinence from alcohol and recreational drugs, stress management, light therapy for depression with seasonal pattern, mood charting/tracking, and maintaining consistent daily routines [65]. These complement but do NOT replace medication for most people [65].

Q43. Why is sleep so important in bipolar?

Sleep disruption is one of the strongest triggers for both manic and depressive episodes [67]. Even one or two nights of reduced sleep can precipitate mania in vulnerable individuals. Conversely, mania reduces sleep need, creating a dangerous spiral. Maintaining consistent 7–9 hours of sleep nightly is a cornerstone of bipolar self-management [67][68].

Q44. How does substance use affect bipolar?

Research shows a strong association between bipolar disorder and substance use problems [160]. Alcohol, cannabis, and stimulants worsen course, increase suicide risk, reduce medication response, and trigger episodes [69]. Cannabis use, in particular, has been shown to advance age of onset and increase psychotic symptoms [69]. Treating both conditions simultaneously (integrated dual-diagnosis treatment) gives best outcomes [70].

Q45. How does bipolar affect relationships?

Bipolar can strain relationships through episodes (irritability, withdrawal, risky behaviors during mania, depressive isolation), but stable relationships are absolutely possible and protective [71]. Family-focused therapy reduces relapse rates significantly; communication skills, education for partners/family, and crisis planning help [71][72]. Couples can thrive with mutual understanding and treatment compliance [72].

Q46. Should I tell my employer about my bipolar disorder?

Disclosure is personal — there’s no legal obligation in most jurisdictions [73]. The ADA (US), Equality Act (UK), and similar laws prohibit discrimination based on mental illness. Disclosure is required only to access formal accommodations. Many people disclose selectively to trusted colleagues, HR for accommodations, or not at all. Working with a clinician on a disclosure plan is helpful [73].

Q47. Can people with bipolar have children?

Yes — many do. Working with a perinatal psychiatrist before pregnancy is recommended [74].

Q48. What is a “wellness plan” or “WRAP” for bipolar?

Wellness Recovery Action Plan (WRAP), developed by Mary Ellen Copeland, is a self-management tool involving: identifying personal warning signs, daily wellness routines, triggers and how to address them, an action plan for early warning signs, a crisis plan, and a post-crisis plan [75]. RCT evidence supports its use as an adjunct to clinical treatment [75].

Q49. Where can I find support and community?

Reputable resources: Depression and Bipolar Support Alliance (DBSA, dbsalliance.org), International Bipolar Foundation (ibpf.org), NAMI (nami.org), MoodNetwork, and ISBD (isbd.org) [76]. Peer support groups (in-person and online) significantly improve outcomes per multiple studies. Avoid social media groups that promote untreated approaches or pseudoscience [76][77].

Q50. What’s the biggest message you’d give someone newly diagnosed with bipolar?

Three points emphasized in major patient guidelines [22][31][49]: (1) You did not cause this and you cannot will it away — it’s a treatable medical condition. (2) With proper treatment, full lives are achievable; treatment is most effective early, so don’t delay. (3) Education, routine, support, and partnership with a knowledgeable psychiatrist make the difference. Stigma is the enemy; science is your ally.
Key takeaway: Bipolar disorder is a treatable, brain-based illness — not a character flaw, mood swing, or creative quirk. Modern medicine and therapy can transform outcomes. Stigma harms; education heals.

Complete Reference List

All 150 citations from peer-reviewed scientific journals and authoritative bodies (APA, NIMH, ISBD, CANMAT, NICE, Lancet, JAMA, NEJM, Bipolar Disord, Mol Psychiatry).
  1. Plans L, et al. Association between completed suicide and bipolar disorder: a systematic review of the literature. J Affect Disord. 2019;242:111-122.
  2. Cipriani A, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.
  3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). APA Publishing; 2022.
  4. World Health Organization. (2019). International Classification of Diseases 11th Revision (ICD-11). https://icd.who.int/en
  5. GBD 2019 Mental Disorders Collaborators. (2022). Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. The Lancet Psychiatry. https://www.healthdata.org/node/9230
  6. Vieta E, Suppes T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord. 2008;10(1 Pt 2):163-178.
  7. Mitchell PB, et al. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord. 2004;6(6):530-539.
  8. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249-62. doi:10.1176/appi.ajp.2013.13020185 PMID: 24030475.
  9. Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: challenges and future directions. Lancet. 2013;381(9878):1663-1671.
  10. Hirschfeld RM, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000;157(11):1873-1875.
  11. Angst J, et al. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord. 2005;88(2):217-233.
  12. Hirschfeld RM, et al. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey. J Clin Psychiatry. 2003;64(2):161-174.
  13. Drancourt N, Etain B, Lajnef M, Henry C, Raust A, Cochet B, et al. Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment. Acta Psychiatr Scand. 2012;127(2):136-144. doi:10.1111/j.1600-0447.2012.01917.x
  14. Bellivier F, et al. Age at onset in bipolar I affective disorder: further evidence for three subgroups. Am J Psychiatry. 2003;160(5):999-1001.
  15. Corrigan PW, et al. Challenging the public stigma of mental illness: a meta-analysis of outcome studies. Psychiatr Serv. 2012;63(10):963-973.
  16. Fazel S, Grann M. The population impact of severe mental illness on violent crime. Am J Psychiatry. 2006;163(8):1397-1403.
  17. Khalifeh H, et al. Violent and non-violent crime against adults with severe mental illness. Br J Psychiatry. 2015;206(4):275-282.
  18. McGuffin P, et al. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry. 2003;60(5):497-502.
  19. Phillips ML, Swartz HA. A Critical Appraisal of Neuroimaging Studies of Bipolar Disorder: Toward a New Conceptualization of Underlying Neural Circuitry and a Road Map for Future Research. AJP. 2014;171(8):829-843. doi:10.1176/appi.ajp.2014.13081008
  20. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2nd ed. Oxford University Press; 2007.
  21. Kyaga S, et al. Mental illness, suicide and creativity: 40-year prospective total population study. J Psychiatr Res. 2013;47(1):83-90.
  22. Andreasen NC. The relationship between creativity and mood disorders. Dialogues Clin Neurosci. 2008;10(2):251-255.
  23. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672-1682.
  24. Robinson LJ, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord. 2006;93(1-3):105-115.
  25. National Institute of Mental Health. Bipolar Disorder Statistics. NIMH. 2024.
  26. Daruy-Filho L, et al. Childhood maltreatment and clinical outcomes of bipolar disorder. Acta Psychiatr Scand. 2011;124(6):427-434.
  27. Tondo L, Baldessarini RJ. Discontinuing psychotropic drug treatment. BJPsych Open. 2020;6(2):e24. doi:10.1192/bjo.2020.6
  28. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170. doi:10.1111/bdi.12609 PMID: 29536616.
  29. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019;51(5):793-803. doi:10.1038/s41588-019-0397-8 PMID: 31043756.
  30. Proudfoot J, et al. Triggers of mania and depression in young adults with bipolar disorder. J Affect Disord. 2012;143(1-3):196-202.
  31. Geoffroy PA, et al. Seasonality and bipolar disorder: a systematic review, from admission rates to seasonality of symptoms. J Affect Disord. 2014;168:210-223.
  32. Carvalho AF, et al. Rapid cycling in bipolar disorder: a systematic review. J Clin Psychiatry. 2014;75(6):e578-586.
  33. Calabrese JR, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry. 2005;162(11):2152-2161.
  34. Goldberg JF, Perlis RH, Bowden CL, Thase ME, Miklowitz DJ, Marangell LB, et al. Manic Symptoms During Depressive Episodes in 1,380 Patients With Bipolar Disorder: Findings From the STEP-BD. AJP. 2009;166(2):173-181. doi:10.1176/appi.ajp.2008.08050746
  35. Judd LL, et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol. 2003;6(2):127-137.
  36. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev. 2007;31(6):858-873.
  37. Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005;67(1):1-8.
  38. Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009;60(2):147-156.
  39. Smith KA, Cipriani A. Lithium and suicide in mood disorders: updated meta-review of the scientific literature. Bipolar Disord. 2017;19(8):575-586.
  40. Goodwin GM, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495-553.
  41. Nivoli AM, et al. Lithium: still a cornerstone in the long-term treatment in bipolar disorder. Neuropsychobiology. 2010;62(1):27-35.
  1. Severus E, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord. 2014;2:15.
  2. Vieta E, Popovic D, Rosa A, Solé B, Grande I, Frey B, et al. The Clinical Implications Of Cognitive Impairment and Allostatic Load in Bipolar Disorder. Eur. psychiatr.. 2012;28(1):21-29. doi:10.1016/j.eurpsy.2011.11.007
  3. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249-62. doi:10.1176/appi.ajp.2013.13020185 PMID: 24030475.
  4. Loebel A, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160-168.
  5. Miklowitz DJ, et al. Adjunctive psychotherapy for bipolar disorder: a systematic review and component network meta-analysis. JAMA Psychiatry. 2021;78(2):141-150.
  6. Frank E, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005;62(9):996-1004.
  7. Versiani M, Cheniaux E, Landeira-Fernandez J. Efficacy and Safety of Electroconvulsive Therapy in the Treatment of Bipolar Disorder: A Systematic Review. The Journal of ECT. 2011;27(2):153-164. doi:10.1097/yct.0b013e3181e6332e
  8. Petrides G, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17(4):244-253.
  9. McGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2014). A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine, 45(4), 693–704. https://doi.org/10.1017/s0033291714001603
  10. Rosenblat JD, Kakar R, McIntyre RS. The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. IJNPPY. 2015;19(2):pyv082. doi:10.1093/ijnp/pyv082
  11. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757-777. doi:10.2147/TCRM.S117321 PMID: 28721057.
  12. Goodwin G. Evidence-based guidelines for treating bipolar disorder: revised second edition—recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346-388. doi:10.1177/0269881109102919
  13. Frank E, Hlastala S, Ritenour A, Houck P, Xin Ming Tu , Monk TH, et al. Inducing lifestyle regularity in recovering bipolar disorder patients: Results from the maintenance therapies in bipolar disorder protocol. Biological Psychiatry. 1997;41(12):1165-1173. doi:10.1016/s0006-3223(96)00241-7
  14. Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry. 2008;165(7):820-829.
  15. Wehr TA, Sack DA, Rosenthal NE. Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry. 1987;144(2):201-4. doi:10.1176/ajp.144.2.201 PMID: 3812788.
  16. Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE, et al. Effects of Co-occurring Cannabis Use Disorders on the Course of Bipolar Disorder After a First Hospitalization for Mania. Arch Gen Psychiatry. 2007;64(1):57. doi:10.1001/archpsyc.64.1.57
  17. Drake RE, Mueser KT, Brunette MF, McHugo GJ. A Review of Treatments for People with Severe Mental Illnesses and Co-Occurring Substance Use Disorders. Psychiatric Rehabilitation Journal. 2004;27(4):360-374. doi:10.2975/27.2004.360.374
  18. Miklowitz DJ. The role of family in the course and treatment of bipolar disorder. Curr Dir Psychol Sci. 2007;16(4):192-196.
  19. Reinares M, Colom F, Sánchez‐Moreno J, Torrent C, Martínez‐Arán A, Comes M, et al. Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial. Bipolar Disorders. 2008;10(4):511-519. doi:10.1111/j.1399-5618.2008.00588.x
  20. Brohan E, Evans-Lacko S, Henderson C, Murray J, Slade M, Thornicroft G. Disclosure of a mental health problem in the employment context: qualitative study of beliefs and experiences. Epidemiol Psychiatr Sci. 2013;23(3):289-300. doi:10.1017/s2045796013000310
  21. Wesseloo R, et al. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(2):117-127.
  22. Cook JA, Copeland ME, Jonikas JA, Hamilton MM, Razzano LA, Grey DD, et al. Results of a Randomized Controlled Trial of Mental Illness Self-management Using Wellness Recovery Action Planning. Schizophrenia Bulletin. 2011;38(4):881-891. doi:10.1093/schbul/sbr012
  23. Depression and Bipolar Support Alliance. (n.d.). About DBSA. https://www.dbsalliance.org/about/
  24. Pfeiffer PN, et al. Efficacy of peer support interventions for depression: a meta-analysis. Gen Hosp Psychiatry. 2011;33(1):29-36.
  1. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64(5):543-52. doi:10.1001/archpsyc.64.5.543 PMID: 17485606.
  2. National Institute for Health and Care Excellence. (2014). Bipolar disorder: assessment and management (CG185). https://www.nice.org.uk/guidance/cg185
  3. International Society for Bipolar Disorders. (2026). About ISBD’s Mission & Impact. https://www.isbd.org/about-us/
  4. Merikangas, K. R., Jin, R., He, J.-P., Kessler, R. C., Lee, S., Sampson, N. A., Viana, M. C., Andrade, L. H., Hu, C., Karam, E. G., Ladea, M., Medina-Mora, M. E., Ono, Y., Posada-Villa, J., Sagar, R., Wells, J. E., & Zarkov, Z. (2011). Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Archives of General Psychiatry 68(3), 241. https://doi.org/10.1001/archgenpsychiatry.2011.12
  5. Hirschfeld, R. M. A., Lewis, L., & Vornik, L. A. (2003). Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. Journal of Clinical Psychiatry 64(2), 161-174. PMID 12633125
  6. McGuffin, P., Rijsdijk, F., Andrew, M., Sham, P., Katz, R., & Cardno, A. (2003). The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Archives of General Psychiatry 60(5), 497. https://doi.org/10.1001/archpsyc.60.5.497
  7. National Institute of Mental Health. (n.d.). Bipolar disorder. https://www.nimh.nih.gov/health/statistics/bipolar-disorder
  8. Carvalho, A. F., Dimellis, D., Gonda, X., Vieta, E., McIntyre, R. S., & Fountoulakis, K. N. (2014). Rapid cycling in bipolar disorder: A systematic review. Journal of Clinical Psychiatry 75(6), e578-e586. https://doi.org/10.4088/JCP.13r08905
  9. Plans, L., Barrot, C., Nieto, E., Rios, J., Schulze, T. G., Papiol, S., Mitjans, M., Vieta, E., & Benabarre, A. (2018). Association between completed suicide and bipolar disorder: A systematic review of the literature. Journal of Affective Disorders 242, 111-122. https://doi.org/10.1016/j.jad.2018.08.054
  10. Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013). Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 346, f3646. https://doi.org/10.1136/bmj.f3646
  11. Miklowitz, D. J., Efthimiou, O., Furukawa, T. A., Scott, J., McLaren, R., Geddes, J. R., & Cipriani, A. (2020). Adjunctive psychotherapy for bipolar disorder. JAMA Psychiatry 78(2), 141. https://doi.org/10.1001/jamapsychiatry.2020.2993
  12. Perugi, G., Medda, P., Toni, C., Mariani, M., Socci, C., & Mauri, M. (2017). The role of electroconvulsive therapy (ECT) in bipolar disorder: Effectiveness in 522 patients with bipolar depression, mixed-state, mania and catatonic features. Current Neuropharmacology 15(3), 359-371. https://doi.org/10.2174/1570159X14666161017233642
  13. Krishnan, K. R. R. (2005). Psychiatric and medical comorbidities of bipolar disorder. Psychosomatic Medicine 67(1), 1-8. https://doi.org/10.1097/01.psy.0000151489.36347.18
  14. National Institute of Mental Health. (n.d.). Bipolar disorder. https://www.nimh.nih.gov/health/statistics/bipolar-disorder

Get Specialized Support for Bipolar Disorder

If you or a loved one is navigating bipolar disorder, expert care makes a profound difference. Our practice provides evidence-based therapy and support tailored to bipolar I, II, cyclothymia, and family members. Book a Free Intro Call →
This page is for general-interest purposes only and does not replace professional medical or mental-health advice. Bipolar treatment requires psychiatric supervision. If you are in crisis, call 911 immediately.

Ready to talk? Your first 20 minutes are free. Call or text any day between 9am and 9pm.

6047210604

[email protected]

25+
years clinical
Doctorate
LMCC · FSMB verified
2
languages — EN · فارسی
3
countries · frontline trauma
Therapy+
neurofeedback, one practice

Who you’re talking to

I’m Samuel Ezzatilord, PhD, RCC, CCC, LMCC. Over 25 years I’ve worked with trauma, anxiety, and relationships — from Red Crescent refugee camps and veterans’ clinics to community mental health here in Vancouver. I won’t be shocked by what you bring me, and I won’t rush you.

As an Iranian-Canadian clinician working in both English and Farsi, I understand the weight of آبرو, the pull between cultures, and how hard it can be to say “I need help” out loud. We go at your pace, find what’s really driving things, and work through it together.

My full story →

And no — your problem doesn’t need to be a crisis to belong here.

What happens when you call?

1
You call or text.

Dr. Samuel answers personally. No secretary, no forms, no gatekeeping.

2
You talk — 20 minutes, free.

Ask anything: fees, insurance, whether this approach fits you. Confidential within the limits of BC law and professional ethics.

3
You decide.

Book a first session — or don’t. Either way you leave with clarity and zero obligation.

Fees may be covered, depending on eligibility, by ICBC, CVAP, FNHA, IFHP, RCMP, VAC, and most other insurers, and direct billing is available.

سلب مسئولیت: محتوای این صفحه صرفاً جنبهٔ آشنایی عمومی دارد و جایگزین مشاوره، تشخیص یا درمان حرفه‌ای نیست. برای هرگونه تصمیم مربوط به سلامت روان، با یک متخصص واجد صلاحیت مشورت کنید.

Disclaimer: This page is for general-interest purposes only and does not constitute professional advice, diagnosis, or treatment. Consult a qualified professional for any mental-health decisions.

نوشته شده با همکاری تحریریه تخصصی · Written with expert editorial assistance

Notice: For general interest only; may contain inaccuracies. Not a diagnosis, treatment, prognosis, or professional, clinical, or legal advice. Reading this creates no counsellor-client relationship. By reading this page, you agree to these terms. Full disclaimer. In an emergency, call 911.

This page provides general information only and is not medical, psychological or legal advice.

این صفحه صرفاً اطلاعات عمومی ارائه می‌دهد و توصیه پزشکی، روان‌شناختی یا حقوقی نیست.

Dr SamuelCounselling · Therapy · Neurofeedback Certified Trauma Professional (CTP) — Evergreen CertificationsCertified Youth Mental Health Specialist (CYMHS) — Evergreen CertificationsCertified in Dialectical Behavior Therapy (C-DBT) — Evergreen Certifications
Call Now — FreeDirect line · No formsتماس مستقیم با ساموئل بدون دخالت منشی WhatsApp / Textواتساپ / پیامک Request a Callbackدرخواست تماس کتبی

Suite 1300, 1500 West Georgia Street, Vancouver, BC

6047210604

[email protected]

AFFILIATED WITH
BCACC
RCC
BCACC RCC
CCPA
CCC
CCPA CCC
✚
Red Cross (IFRC)
⛰
Hollyburn Support
☀
Sun Life Lumino
SHIFA
Shifa Therapy
FNHA
FNHA Provider
Scroll to Top